Aducanumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | beta amyloid |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| Synonyms | BIIB037 |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H10028N1740O2014S46 |
| Molar mass | 145.9 kg/mol |
Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD). It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.
Interim results from the second Phase 1 study of the drug were reported in March 2015.
A phase Ib study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques. Phase 3 clinical trials are ongoing.
...
Wikipedia